The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is there any difference in overall response rate according to kras mutation in advanced colorectal cancer (aCRC)?
José Antonio Rivadeneira Cabana
No relevant relationships to disclose
Antonio Viudez
No relevant relationships to disclose
David Guerrero
No relevant relationships to disclose
Irene Hernandez
No relevant relationships to disclose
Maria Luisa Gomez Dorronsoro
No relevant relationships to disclose
Marta Montes
No relevant relationships to disclose
Juan Verdun
No relevant relationships to disclose
Antonio Tarifa
No relevant relationships to disclose
Javier Suarez
No relevant relationships to disclose
Angela Fernandez de Lascoiti
No relevant relationships to disclose
Miguel Angel Ciga Lozano
No relevant relationships to disclose
Ruth Vera
No relevant relationships to disclose